There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Keryx Biopharma (NASDAQ:KERX) and AVEO Pharma (NASDAQ:AVEO) with bullish sentiments.
Keryx Biopharma (KERX)
H.C. Wainwright analyst Jason Kolbert maintained a Buy rating on Keryx Biopharma today and set a price target of $9. The company’s shares closed yesterday at $3.18, close to its 52-week low of $2.78.
Kolbert wrote:
“Valuation compelling. Keryx stock price has pulled back since the merger was announced however we see only improving fundamentals. As such we make no changes to our valuation metrics which are based on our therapeutic models, which are patient-based and reflect our assumptions for the market size and share penetration rates and pricing.”
According to TipRanks.com, Kolbert is ranked 0 out of 5 stars with an average return of -3.3% and a 38.4% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Cytori Therapeutics Inc, Anavex Life Sciences, and Coherus Biosciences.
Currently, the analyst consensus on Keryx Biopharma is a Moderate Buy with an average price target of $9.
See today’s analyst top recommended stocks >>
AVEO Pharma (AVEO)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on AVEO Pharma, with a price target of $6.50. The company’s shares closed yesterday at $2.97.
Ramakanth commented:
“We maintain our Buy rating on AVEO and our 12-month price target of $6.50 per share. We derive our price target based on a risk-adjusted NPV analysis of projected tivozanib and ficlatuzumab revenues through 2030 assuming a 12.5% discount rate and 3% terminal growth rate. We derive an rNPV of $1.1B for the products and add in cash and cash equivalents of $18M to arrive at a 12-month price target of $6.42 per diluted share, which we round to $6.50.”
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 7.2% and a 41.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Trillium Therapeutics.
Currently, the analyst consensus on AVEO Pharma is a Strong Buy with an average price target of $5.50, an 85.2% upside from current levels. In a report released yesterday, Piper Jaffray also reiterated a Buy rating on the stock with a $5 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
